Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.

Menzies-Gow, Andrew

Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. [electronic resource] - The Journal of allergy and clinical immunology Apr 2003 - 714-9 p. digital

Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial

0091-6749

10.1067/mai.2003.1382 doi


Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Humanized
Antigens, CD34--analysis
Asthma--blood
Bone Marrow Cells--drug effects
Bronchi--drug effects
Double-Blind Method
Eosinophils--drug effects
Hematopoietic Stem Cells--drug effects
Humans
Interleukin-5--analysis